Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat Genet. 2023 Mar 21.
View in:
PubMed
Author Correction: Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet. 2023 Mar 21.
View in:
PubMed
ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma. Clin Cancer Res. 2023 Feb 13.
View in:
PubMed
Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2023 Feb; 614(7948):E40.
View in:
PubMed
Author Correction: Patterns of somatic structural variation in human cancer genomes. Nature. 2023 Feb; 614(7948):E38.
View in:
PubMed
Author Correction: The evolutionary history of 2,658 cancers. Nature. 2023 Feb; 614(7948):E42.
View in:
PubMed
Tangent normalization for somatic copy-number inference in cancer genome analysis. Bioinformatics. 2022 10 14; 38(20):4677-4686.
View in:
PubMed
VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system. JCI Insight. 2022 10 10; 7(19).
View in:
PubMed
Patterns of structural variation define prostate cancer across disease states. JCI Insight. 2022 09 08; 7(17).
View in:
PubMed
The genomic landscape of dysembryoplastic neuroepithelial tumours and a comprehensive analysis of recurrent cases. Neuropathol Appl Neurobiol. 2022 10; 48(6):e12834.
View in:
PubMed
Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine. Neuro Oncol. 2022 08 01; 24(8):1352-1363.
View in:
PubMed
Analysis of germline-driven ancestry-associated gene expression in cancers. STAR Protoc. 2022 09 16; 3(3):101586.
View in:
PubMed
Publisher Correction: DNA-based copy number analysis confirms genomic evolution of PDX models. NPJ Precis Oncol. 2022 Jul 12; 6(1):50.
View in:
PubMed
Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. Nat Cancer. 2022 08; 3(8):994-1011.
View in:
PubMed
Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. Neuro Oncol. 2022 07 01; 24(7):1140-1149.
View in:
PubMed
Structural variations in cancer and the 3D genome. Nat Rev Cancer. 2022 09; 22(9):533-546.
View in:
PubMed
A molecularly integrated grade for meningioma. Neuro Oncol. 2022 05 04; 24(5):796-808.
View in:
PubMed
Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clin Cancer Res. 2022 05 02; 28(9):1911-1924.
View in:
PubMed
DNA-based copy number analysis confirms genomic evolution of PDX models. NPJ Precis Oncol. 2022 Apr 28; 6(1):30.
View in:
PubMed
PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nat Commun. 2022 02 01; 13(1):604.
View in:
PubMed
Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2022 01 05; 24(1):101-113.
View in:
PubMed
Analytical protocol to identify local ancestry-associated molecular features in cancer. STAR Protoc. 2021 12 17; 2(4):100766.
View in:
PubMed
Quantification of aneuploidy in targeted sequencing data using ASCETS. Bioinformatics. 2021 08 25; 37(16):2461-2463.
View in:
PubMed
Haplotype-resolved germline and somatic alterations in renal medullary carcinomas. Genome Med. 2021 07 14; 13(1):114.
View in:
PubMed
TIRR inhibits the 53BP1-p53 complex to alter cell-fate programs. Mol Cell. 2021 06 17; 81(12):2583-2595.e6.
View in:
PubMed
Integrative modeling identifies genetic ancestry-associated molecular correlates in human cancer. STAR Protoc. 2021 06 18; 2(2):100483.
View in:
PubMed
Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell. 2021 04 15; 184(8):2239-2254.e39.
View in:
PubMed
Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway. Cell Rep. 2021 Feb 23; 34(8):108784.
View in:
PubMed
Whole-genome characterization of lung adenocarcinomas lacking the RTK/RAS/RAF pathway. Cell Rep. 2021 02 02; 34(5):108707.
View in:
PubMed
Aneuploidy renders cancer cells vulnerable to mitotic checkpoint inhibition. Nature. 2021 02; 590(7846):486-491.
View in:
PubMed
Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell. 2020 12 10; 183(6):1617-1633.e22.
View in:
PubMed
CloneSifter: enrichment of rare clones from heterogeneous cell populations. BMC Biol. 2020 11 24; 18(1):177.
View in:
PubMed
Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. Cell. 2020 10 01; 183(1):197-210.e32.
View in:
PubMed
Author Correction: Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat Genet. 2020 Jul; 52(7):748-749.
View in:
PubMed
Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. Mol Cell. 2020 06 18; 78(6):1207-1223.e8.
View in:
PubMed
Ancestry-specific predisposing germline variants in cancer. Genome Med. 2020 05 29; 12(1):51.
View in:
PubMed
Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities. Nat Commun. 2020 05 20; 11(1):2517.
View in:
PubMed
Cas9 activates the p53 pathway and selects for p53-inactivating mutations. Nat Genet. 2020 07; 52(7):662-668.
View in:
PubMed
Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. Cancer Cell. 2020 05 11; 37(5):639-654.e6.
View in:
PubMed
Targeting Cancer Gene Dependencies with Anthrax-Mediated Delivery of Peptide Nucleic Acids. ACS Chem Biol. 2020 06 19; 15(6):1358-1369.
View in:
PubMed
Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523.
View in:
PubMed
The evolutionary history of 2,658 cancers. Nature. 2020 02; 578(7793):122-128.
View in:
PubMed
Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat Genet. 2020 03; 52(3):294-305.
View in:
PubMed
Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2020 02; 578(7793):102-111.
View in:
PubMed
Patterns of somatic structural variation in human cancer genomes. Nature. 2020 02; 578(7793):112-121.
View in:
PubMed
Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet. 2020 03; 52(3):306-319.
View in:
PubMed
Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. Nat Genet. 2020 02; 52(2):219-230.
View in:
PubMed
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 2020 01 13; 37(1):104-122.e12.
View in:
PubMed
Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019 12; 576(7785):112-120.
View in:
PubMed
Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma. Cancer Med. 2019 10; 8(13):5988-5994.
View in:
PubMed
Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Nat Commun. 2019 08 19; 10(1):3731.
View in:
PubMed
Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro Oncol. 2019 08 05; 21(8):968-980.
View in:
PubMed
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nat Commun. 2019 06 03; 10(1):2400.
View in:
PubMed
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. Science. 2019 03 15; 363(6432):1217-1222.
View in:
PubMed
Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 03 12; 8.
View in:
PubMed
MCL1 and DEDD Promote Urothelial Carcinoma Progression. Mol Cancer Res. 2019 06; 17(6):1294-1304.
View in:
PubMed
Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750.
View in:
PubMed
Genomic evolution of cancer models: perils and opportunities. Nat Rev Cancer. 2019 02; 19(2):97-109.
View in:
PubMed
miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma. Oncogene. 2019 04; 38(16):2923-2936.
View in:
PubMed
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. Cancer Cell. 2018 12 10; 34(6):922-938.e7.
View in:
PubMed
PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. Clin Cancer Res. 2019 01 01; 25(1):334-345.
View in:
PubMed
Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med. 2018 Oct; 24(10):1627.
View in:
PubMed
Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018 08; 560(7718):325-330.
View in:
PubMed
Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1290-1291.
View in:
PubMed
Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1292.
View in:
PubMed
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018 Jun 19; 23(12):3698.
View in:
PubMed
Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell. 2018 07 12; 174(2):433-447.e19.
View in:
PubMed
Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. Neuro Oncol. 2018 06 18; 20(7):873-884.
View in:
PubMed
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.
View in:
PubMed
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med. 2018 07; 24(7):968-977.
View in:
PubMed
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 05; 24(5):679-690.
View in:
PubMed
Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018 04 20; 360(6386):331-335.
View in:
PubMed
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep. 2018 04 03; 23(1):313-326.e5.
View in:
PubMed
Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell. 2018 04 09; 33(4):676-689.e3.
View in:
PubMed
SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Res. 2018 04; 28(4):581-591.
View in:
PubMed
Radiographic prediction of meningioma grade by semantic and radiomic features. PLoS One. 2017; 12(11):e0187908.
View in:
PubMed
Open data: Spot data glitches before publication. Nature. 2017 10 18; 550(7676):333.
View in:
PubMed
Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017 Nov; 49(11):1567-1575.
View in:
PubMed
Erratum: Genomic landscape of high-grade meningiomas. NPJ Genom Med. 2017; 2:26.
View in:
PubMed
The whole-genome landscape of medulloblastoma subtypes. Nature. 2017 07 19; 547(7663):311-317.
View in:
PubMed
Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. Endocrinology. 2017 07 01; 158(7):2284-2291.
View in:
PubMed
Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. Neuro Oncol. 2017 Jul 01; 19(7):908-917.
View in:
PubMed
Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 2017 Jul 01; 19(7):986-996.
View in:
PubMed
Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep. 2017 06 30; 7:46873.
View in:
PubMed
Genomic profile of human meningioma cell lines. PLoS One. 2017; 12(5):e0178322.
View in:
PubMed
MicroRNA Signatures and Molecular Subtypes of Glioblastoma: The Role of Extracellular Transfer. Stem Cell Reports. 2017 06 06; 8(6):1497-1505.
View in:
PubMed
Genomic landscape of high-grade meningiomas. NPJ Genom Med. 2017; 2.
View in:
PubMed
Somatic copy number alterations in gastric adenocarcinomas among Asian and Western patients. PLoS One. 2017; 12(4):e0176045.
View in:
PubMed
Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 04 01; 19(4):535-545.
View in:
PubMed
SeqLib: a C?++ API for rapid BAM manipulation, sequence alignment and sequence assembly. Bioinformatics. 2017 03 01; 33(5):751-753.
View in:
PubMed
Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. Elife. 2017 02 08; 6.
View in:
PubMed
Copy number alterations unmasked as enhancer hijackers. Nat Genet. 2016 12 28; 49(1):5-6.
View in:
PubMed
Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis. Neoplasia. 2017 02; 19(2):75-83.
View in:
PubMed
Genomic evolution and chemoresistance in germ-cell tumours. Nature. 2016 11 30; 540(7631):114-118.
View in:
PubMed
Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat Genet. 2017 01; 49(1):10-16.
View in:
PubMed
Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer. Clin Cancer Res. 2017 May 01; 23(9):2367-2373.
View in:
PubMed
The genomic landscape of schwannoma. Nat Genet. 2016 11; 48(11):1339-1348.
View in:
PubMed
Landscape of Genomic Alterations in Pituitary Adenomas. Clin Cancer Res. 2017 Apr 01; 23(7):1841-1851.
View in:
PubMed
Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 01; 19(1):22-30.
View in:
PubMed
The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat Genet. 2016 08; 48(8):848-55.
View in:
PubMed
Corrigendum: Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep. 2016 06 24; 6:27960.
View in:
PubMed
MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma. Oncotarget. 2016 Jun 14; 7(24):37054-37063.
View in:
PubMed
Recurrent hormone-binding domain truncated ESR1 amplifications in primary endometrial cancers suggest their implication in hormone independent growth. Sci Rep. 2016 05 10; 6:25521.
View in:
PubMed
Characterizing genomic alterations in cancer by complementary functional associations. Nat Biotechnol. 2016 05; 34(5):539-46.
View in:
PubMed
Genomic and Epigenomic Landscape in Meningioma. Neurosurg Clin N Am. 2016 Apr; 27(2):167-79.
View in:
PubMed
CANCER. The oncogene makes its escape. Science. 2016 Mar 25; 351(6280):1398-9.
View in:
PubMed
Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. J Neurooncol. 2016 06; 128(2):293-302.
View in:
PubMed
VariantBam: filtering and profiling of next-generational sequencing data using region-specific rules. Bioinformatics. 2016 07 01; 32(13):2029-31.
View in:
PubMed
MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet. 2016 Mar; 48(3):273-82.
View in:
PubMed
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 05; 18(5):649-55.
View in:
PubMed
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 2016 Jan 28; 164(3):550-63.
View in:
PubMed
Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. Diagn Pathol. 2016 Jan 27; 11:13.
View in:
PubMed
Genomic landscape of intracranial meningiomas. J Neurosurg. 2016 09; 125(3):525-35.
View in:
PubMed
Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol. 2016 Jan; 126(1):165-174.
View in:
PubMed
MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy. Cancer Discov. 2016 Jan; 6(1):45-58.
View in:
PubMed
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med. 2016 Jan 14; 374(2):135-45.
View in:
PubMed
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
View in:
PubMed
Exome sequencing of lymphomas from three dog breeds reveals somatic mutation patterns reflecting genetic background. Genome Res. 2015 Nov; 25(11):1634-45.
View in:
PubMed
A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74.
View in:
PubMed
Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer. 2015 Dec 15; 121(24):4376-81.
View in:
PubMed
Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Nat Struct Mol Biol. 2015 Sep; 22(9):703-711.
View in:
PubMed
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015 Jun 25; 372(26):2481-98.
View in:
PubMed
Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation. J Neurooncol. 2015 Aug; 124(1):137-46.
View in:
PubMed
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2015 Aug 15; 21(16):3610-8.
View in:
PubMed
Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncol. 2015 Nov; 17(11):1486-96.
View in:
PubMed
ARID1A and TERT promoter mutations in dedifferentiated meningioma. Cancer Genet. 2015 Jun; 208(6):345-50.
View in:
PubMed
Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55.
View in:
PubMed
Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun. 2015 Feb 27; 6:6169.
View in:
PubMed
Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget. 2015 Jan 20; 6(2):1327-39.
View in:
PubMed
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015 Jun; 17(6):862-7.
View in:
PubMed
An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A. 2015 Jan 06; 112(1):232-7.
View in:
PubMed
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6.
View in:
PubMed
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study. J Neurooncol. 2015 Feb; 121(3):627-34.
View in:
PubMed
Prioritizing causal disease genes using unbiased genomic features. Genome Biol. 2014 Dec 03; 15(12):534.
View in:
PubMed
Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget. 2014 Nov 15; 5(21):10596-606.
View in:
PubMed
SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. Mol Cell. 2014 Nov 20; 56(4):595-607.
View in:
PubMed
Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. Oncotarget. 2014 Sep 30; 5(18):8083-92.
View in:
PubMed
Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. Genes Dev. 2014 Sep 01; 28(17):1957-75.
View in:
PubMed
Beating the odds: extreme long-term survival with glioblastoma. Neuro Oncol. 2014 Sep; 16(9):1159-60.
View in:
PubMed
Epigenetic targeting of hedgehog pathway transcriptional output. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii25.
View in:
PubMed
Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med. 2014 Jul; 20(7):732-40.
View in:
PubMed
Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro Oncol. 2014 Nov; 16(11):1523-9.
View in:
PubMed
Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol. 2014 Nov; 16(11):1547-53.
View in:
PubMed
Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nat Genet. 2014 Jun; 46(6):588-94.
View in:
PubMed
Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 2014 Mar 17; 25(3):393-405.
View in:
PubMed
Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: a gene expression imaging study. Epilepsy Res. 2014 Jul; 108(5):843-52.
View in:
PubMed
Pediatric low-grade gliomas: how modern biology reshapes the clinical field. Biochim Biophys Acta. 2014 Apr; 1845(2):294-307.
View in:
PubMed
Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer. 2014 Jul; 61(7):1173-9.
View in:
PubMed
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1102-7.
View in:
PubMed
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell. 2013 Dec 09; 24(6):738-50.
View in:
PubMed
BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res. 2014 Feb 15; 20(4):912-25.
View in:
PubMed
The somatic genomic landscape of glioblastoma. Cell. 2013 Oct 10; 155(2):462-77.
View in:
PubMed
Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013 Oct; 45(10):1134-40.
View in:
PubMed
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013 Oct; 45(10):1113-20.
View in:
PubMed
Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med. 2013 Nov; 19(11):1518-23.
View in:
PubMed
The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell. 2013 Sep 09; 24(3):365-78.
View in:
PubMed
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013 Jul 04; 499(7456):43-9.
View in:
PubMed
Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discov. 2013 Sep; 3(9):1044-57.
View in:
PubMed
Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin Emerg Drugs. 2013 Jun; 18(2):137-53.
View in:
PubMed
Integrated genomic characterization of endometrial carcinoma. Nature. 2013 May 02; 497(7447):67-73.
View in:
PubMed
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8188-93.
View in:
PubMed
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol. 2013 Jul; 15(7):930-5.
View in:
PubMed
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013 May; 45(5):478-86.
View in:
PubMed
Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLoS One. 2013; 8(2):e54873.
View in:
PubMed
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013 Mar; 45(3):285-9.
View in:
PubMed
Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013 Apr; 144(4):829-40.
View in:
PubMed
ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res. 2013 Apr; 23(4):665-78.
View in:
PubMed
ß-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012 Dec 21; 151(7):1457-73.
View in:
PubMed
Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res. 2013 Feb; 23(2):228-35.
View in:
PubMed
Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012 Sep 11; 22(3):359-72.
View in:
PubMed
Cancer vulnerabilities unveiled by genomic loss. Cell. 2012 Aug 17; 150(4):842-54.
View in:
PubMed
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012 Aug 02; 488(7409):49-56.
View in:
PubMed
Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature. 2012 Jul 26; 487(7408):491-5.
View in:
PubMed
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res. 2012 Sep 01; 72(17):4383-93.
View in:
PubMed
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012 Jun 20; 486(7403):405-9.
View in:
PubMed
Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science. 2012 Jul 06; 337(6090):104-9.
View in:
PubMed
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012 May; 30(5):413-21.
View in:
PubMed
Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell. 2012 Apr 17; 21(4):547-62.
View in:
PubMed
Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron. 2012 Apr 12; 74(1):41-8.
View in:
PubMed
A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. PLoS Comput Biol. 2012 Jan; 8(1):e1002337.
View in:
PubMed
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med. 2011 Aug 07; 17(9):1116-20.
View in:
PubMed
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet. 2011 Jul 31; 43(9):869-74.
View in:
PubMed
Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. J Pathol. 2011 Oct; 225(2):212-21.
View in:
PubMed
Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol. 2012 Jan; 106(1):121-5.
View in:
PubMed
Genetic and functional studies implicate HIF1a as a 14q kidney cancer suppressor gene. Cancer Discov. 2011 Aug; 1(3):222-35.
View in:
PubMed
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41.
View in:
PubMed
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature. 2011 Mar 24; 471(7339):513-7.
View in:
PubMed
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010 Dec 15; 2(62):62ra93.
View in:
PubMed
Stathmin is superior to AKT and phospho-AKT staining for the detection of phosphoinositide 3-kinase activation and aggressive endometrial cancer. Histopathology. 2010 Oct; 57(4):641-6.
View in:
PubMed
A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. Proc Natl Acad Sci U S A. 2010 Oct 12; 107(41):17604-9.
View in:
PubMed
Medical therapies for meningiomas. J Neurooncol. 2010 Sep; 99(3):365-78.
View in:
PubMed
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010 Aug; 42(8):715-21.
View in:
PubMed
The design and validation of a novel phenotypic assay to determine HIV-1 coreceptor usage of clinical isolates. J Virol Methods. 2010 Oct; 169(1):39-46.
View in:
PubMed
ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor. Mod Pathol. 2010 Aug; 23(8):1061-7.
View in:
PubMed
The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905.
View in:
PubMed
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med. 2010 Mar; 16(3):286-94.
View in:
PubMed
Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther. 2009 Nov; 8(21):2042-50.
View in:
PubMed
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A. 2009 Oct 27; 106(43):18351-6.
View in:
PubMed
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009 Nov; 41(11):1238-42.
View in:
PubMed
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009 Jul 23; 138(2):245-56.
View in:
PubMed
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell. 2009 Jul 07; 16(1):44-54.
View in:
PubMed
Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 2009 Jul 01; 69(13):5601-9.
View in:
PubMed
Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009 Jun 01; 69(11):4674-81.
View in:
PubMed
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009 Jul; 41(7):843-8.
View in:
PubMed
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest. 2009 Jun; 119(6):1727-40.
View in:
PubMed
Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer. 2009 Apr; 48(4):366-80.
View in:
PubMed
Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res. 2009 Feb 15; 15(4):1417-27.
View in:
PubMed
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol. 2009 Jan; 27(1):77-83.
View in:
PubMed
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20380-5.
View in:
PubMed
High-resolution genomic and expression analyses of copy number alterations in breast tumors. Genes Chromosomes Cancer. 2008 Jun; 47(6):530-42.
View in:
PubMed
Major copy proportion analysis of tumor samples using SNP arrays. BMC Bioinformatics. 2008 Apr 21; 9:204.
View in:
PubMed
SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. Nucleic Acids Res. 2008 Apr; 36(7):2446-56.
View in:
PubMed
HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol. 2008 Feb; 32(2):307-16.
View in:
PubMed
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008 Feb 01; 68(3):664-73.
View in:
PubMed
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):20007-12.
View in:
PubMed
Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007 Dec 06; 450(7171):893-8.
View in:
PubMed
Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia. 2007 Mar; 9(3):200-6.
View in:
PubMed
Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007 Mar; 11(3):259-73.
View in:
PubMed
High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51.
View in:
PubMed
Single nucleotide polymorphism array analysis of cancer. Curr Opin Oncol. 2007 Jan; 19(1):43-9.
View in:
PubMed
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006 Dec; 3(12):e485.
View in:
PubMed
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006 Sep 01; 66(17):8337-41.
View in:
PubMed
Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol. 2006 May; 2(5):e41.
View in:
PubMed
Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer. 2005 Dec; 44(4):351-64.
View in:
PubMed
Allele-specific amplification in cancer revealed by SNP array analysis. PLoS Comput Biol. 2005 Nov; 1(6):e65.
View in:
PubMed
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005 Nov 10; 353(19):2012-24.
View in:
PubMed
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005 Jul 07; 436(7047):117-22.
View in:
PubMed
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 2005 Jul 01; 65(13):5561-70.
View in:
PubMed
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004 Jul; 6(1):17-32.
View in:
PubMed
Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res. 2004 Jun 01; 64(11):3814-22.
View in:
PubMed
Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res. 2004 May 18; 32(9):e71.
View in:
PubMed
Neonatal thyrotoxicosis and conjugated hyperbilirubinemia. J Matern Fetal Neonatal Med. 2003 Jun; 13(6):426-8.
View in:
PubMed